dc.contributor.author
Damm, Oliver
dc.contributor.author
Horn, Johannes
dc.contributor.author
Mikolajczyk, Rafael T.
dc.contributor.author
Kretzschmar, Mirjam E. E.
dc.contributor.author
Kaufmann, Andreas M.
dc.contributor.author
Delere, Yvonne
dc.contributor.author
Ultsch, Bernhard
dc.contributor.author
Wichmann, Ole
dc.contributor.author
Krämer, Alexander
dc.contributor.author
Greiner, Wolfgang
dc.date.accessioned
2018-06-08T10:36:26Z
dc.date.available
2017-10-16T10:39:21.101Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20738
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-24037
dc.description.abstract
Background The aim of this study was to assess the cost-effectiveness of human
papillomavirus (HPV) vaccination in addition to the current cervical cancer
screening programme in Germany using a dynamic transmission model. Methods
Based on a mathematical model simulating the transmission dynamics and the
natural history of HPV infection and associated diseases (cervical
intraepithelial neoplasia, cervical cancer, and genital warts), we estimated
the epidemiological and economic consequences of HPV vaccination with both the
quadrivalent and bivalent vaccines. In our base case analysis, we assessed the
cost-effectiveness of vaccinating 12-year-old girls with a 3-dose schedule. In
sensitivity analysis, we also evaluated the use of a 2-dose schedule and
assessed the impact of vaccinating boys. Results From a health care payer
perspective, incremental cost-effectiveness ratios (ICERs) of a 3-dose
schedule were €34,249 per quality-adjusted life year (QALY) for the bivalent
and €14,711 per QALY for the quadrivalent vaccine. Inclusion of indirect costs
decreased ICERs by up to 40%. When adopting a health care payer perspective,
ICERs of a 2-dose approach decreased to €19,450 per QALY for the bivalent and
to €3645 per QALY for the quadrivalent vaccine. From a societal perspective, a
2-dose approach using the quadrivalent vaccine was a cost-saving strategy
while using the bivalent vaccine resulted in an ICER of €13,248 per QALY.
Irrespective of the perspective adopted, additional vaccination of boys
resulted in ICERs exceeding €50,000 per QALY, except for scenarios with low
coverage (20%) in girls. Conclusions Our model results suggest that routine
HPV vaccination of 12-year-old girls with three doses is likely to be cost-
effective in Germany. Due to the additional impact on genital warts, the
quadrivalent vaccine appeared to be more cost-effective than the bivalent
vaccine. A 2-dose schedule of the quadrivalent vaccine might even lead to cost
savings when adopting a societal perspective. The cost-effectiveness of
additional vaccination of boys was highly dependent on the coverage in girls.
de
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Economic evaluation
dc.subject
Cost-effectiveness
dc.subject
Dynamic transmission mode
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Cost-effectiveness of human papillomavirus vaccination in Germany
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Cost Effectiveness and Resource Allocation. - 15 (2017), Artikel Nr. 18
dcterms.bibliographicCitation.doi
10.1186/s12962-017-0080-9
dcterms.bibliographicCitation.url
http://doi.org/10.1186/s12962-017-0080-9
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000028318
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000008991
dcterms.accessRights.openaire
open access